PGC1α in the kidney

Am J Physiol Renal Physiol. 2018 Jan 1;314(1):F1-F8. doi: 10.1152/ajprenal.00263.2017. Epub 2017 Sep 20.

Abstract

Acute kidney injury (AKI) arising from diverse etiologies is characterized by mitochondrial dysfunction. The peroxisome proliferator-activated receptor γ coactivator-1alpha (PGC1α), a master regulator of mitochondrial biogenesis, has been shown to be protective in AKI. Interestingly, reduction of PGC1α has also been implicated in the development of diabetic kidney disease and renal fibrosis. The beneficial renal effects of PGC1α make it a prime target for therapeutics aimed at ameliorating AKI, forms of chronic kidney disease (CKD), and their intersection. This review summarizes the current literature on the relationship between renal health and PGC1α and proposes areas of future interest.

Keywords: AKI; CKD; PGC1α; kidney; metabolism.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Acute Kidney Injury / metabolism*
  • Acute Kidney Injury / therapy
  • Animals
  • Diabetic Nephropathies / metabolism*
  • Diabetic Nephropathies / therapy
  • Humans
  • Kidney / metabolism*
  • Organelle Biogenesis
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha / metabolism*
  • Renal Insufficiency, Chronic / metabolism*
  • Renal Insufficiency, Chronic / therapy

Substances

  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha